KPV side effects and risks

Reported side effects

• Human adverse-effect rates are unknown: No human safety trial or formal rate estimate. No reports in FDA searches through December 3, 2025 does not prove safety., moderate. Review new symptoms promptly; absence of reports is not evidence of safety. (source)
• Fatigue or symptom flares reported online: Unverified reports; no denominator or confirmed cause., moderate. Stop and seek assessment for worsening symptoms. (source)
• Possible serious allergic reaction: FDA describes immune reaction risk; KPV specific incidence is unknown., serious. Breathing trouble, throat swelling or fainting needs emergency care. (source)

Stop and get help if

• Trouble breathing, throat swelling or collapse: Stop exposure and get emergency help immediately.
• Fever with a spreading hot, painful injection site: Seek urgent care for possible infection.
• New severe or worsening symptoms after use: Stop and obtain medical assessment; do not assume a normal detox reaction.
• Severe belly pain, heavy or nonstop rectal bleeding, or vomiting blood: Get emergency medical help now.
• Bloody diarrhea with fever or a fast heartbeat: Obtain urgent same-day assessment; a severe bowel flare may need hospital care.

Who should avoid it

• pregnant: Precautionary block. No human pregnancy safety studies were found.
• breastfeeding: Precautionary block. Milk transfer and infant effects are unknown.
• tryingToConceive: Precautionary block. Reproductive and developmental safety is unstudied.
• under18: No pediatric dose or safety evidence; adult-only reference.
• melanomaOrAtypicalMoles: Melanoma safety is unstudied. KPV lacks alpha-MSH pigment activity in preclinical work; melanotan risks cannot simply be assigned to KPV.
• kidneyDisease: No human clearance or dose-adjustment data in kidney disease.
• liverDisease: No human clearance or dose-adjustment data in liver disease.
• immunosuppressed: Immune effects and infection risk with immunosuppressive treatment have not been tested in people.
• other: Avoid re-exposure after a suspected serious allergy to KPV or any ingredient.
• testedAthlete: S0 prohibits unapproved pharmacological substances at all times. Verify status with the relevant anti-doping body.

Interactions

• Systemic immunosuppressants: Precaution only. No human interaction data establish how KPV combines with immune-suppressing medicines.

Product quality risks

• FDA found inconsistent KPV naming and incomplete quality data, including missing microbiological tests.
• Unregulated peptides may have the wrong ingredient or amount, microbes, endotoxins, solvents or other contaminants.
• No independent market survey measuring contamination or underdosing of KPV products was found.